JAGSNPHARM — Jagsonpal Pharmaceuticals Balance Sheet
0.000.00%
- IN₹9.87bn
- IN₹8.48bn
- IN₹2.09bn
- 83
- 17
- 53
- 50
Annual balance sheet for Jagsonpal Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2020 March 31st | R2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | Interim Report | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 408 | 637 | 471 | 1,146 | 1,480 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 218 | 127 | 156 | 249 | 110 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 963 | 1,186 | 1,091 | 1,646 | 1,993 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 240 | 233 | 226 | 243 | 93 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 1,487 | 1,648 | 1,642 | 1,949 | 2,171 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 346 | 370 | 270 | 276 | 191 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 377 | 390 | 315 | 361 | 297 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 1,110 | 1,258 | 1,328 | 1,589 | 1,874 |
Total Liabilities & Shareholders' Equity | 1,487 | 1,648 | 1,642 | 1,949 | 2,171 |
Total Common Shares Outstanding |